Quantcast

Latest Otonomy Inc. Stories

2014-07-14 08:26:17

SAN DIEGO, July 14, 2014 /PRNewswire/ -- Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the...

2014-07-08 08:30:02

SAN DIEGO, July 8, 2014 /PRNewswire/ -- Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive results from two identical Phase 3 trials of AuriPro(TM) in a combined total of 532 pediatric patients with bilateral middle ear effusion requiring tympanostomy tube placement. In both trials, AuriPro achieved the primary efficacy...

2014-05-08 08:32:32

SAN DIEGO, May 8, 2014 /PRNewswire/ -- Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment has been completed in its pivotal studies of AuriPro(TM) (previously known as OTO-201) for the treatment of pediatric patients with bilateral middle ear effusion requiring tympanostomy tube placement. http://photos.prnewswire.com/prnvar/20130806/MM59802LOGO The two...

2014-04-30 08:32:42

SAN DIEGO, April 30, 2014 /PRNewswire/ -- Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round of financing. New investors include Jennison Associates LLC (on behalf of clients), Perceptive Advisors, Federated Kaufmann Funds, certain private investment funds advised by Clough Capital Partners LP, Ally Bridge...

2014-03-20 08:29:36

Ms. Capps Brings Experience as Chief Financial Officer and Senior Audit Professional to Position as Chair of Audit Committee SAN DIEGO, March 20, 2014 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Vickie Capps to the company's board of directors. Ms. Capps will assume the position of chair of the audit committee....

2014-02-25 08:31:52

Brings Extensive Experience Leading Manufacturing Operations and Quality Control for Marketed Drug Products SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Robert Savel as chief technical officer. Mr. Savel brings more than 15 years of experience in managing technical operations for marketed drug products,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related